Cadila Healthcare Ltd. plans to submit trial data for its Covid-19 vaccine by end of May and is looking for an approval in June, Financial Express reported citing Sharvil Patel, managing director of Cadila.
The Phase-III clinical trials of the ZyCoV-D vaccine will be representative of its efficacy against many known variants as different ones have surfaced in this wave, Patel told Financial Express.
Cadila Healthcare started producing its potential Covid-19 vaccine last month for which it will seek emergency use authorisation in May or June, with an aim to make up to 240 million doses a year.